These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 38684449)
21. Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis. Doshi BS; Witmer CM Haemophilia; 2021 Jul; 27(4):e551-e553. PubMed ID: 33866659 [No Abstract] [Full Text] [Related]
22. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389 [TBL] [Abstract][Full Text] [Related]
23. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors. Brophy DF; Martin EJ; Kuhn J Haemophilia; 2019 Mar; 25(2):e121-e123. PubMed ID: 30748061 [No Abstract] [Full Text] [Related]
24. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Bowyer A; Kitchen S; Maclean R Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990 [TBL] [Abstract][Full Text] [Related]
26. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557 [TBL] [Abstract][Full Text] [Related]
27. In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot Nakajima Y; Takami E; Nakano H; Nogami K Haemophilia; 2022 Sep; 28(5):e149-e152. PubMed ID: 35947585 [No Abstract] [Full Text] [Related]
28. Interferences by factor VIII and lupus anticoagulant in the modified one-stage assay for emicizumab. Habay C; Auditeau C; Blandinières A; Bentounes NK; Lavenu-Bombled C; Harroche A; Bally C; Frenzel L; Borgel D; Lasne D Haemophilia; 2023 Nov; 29(6):1661-1664. PubMed ID: 37751318 [No Abstract] [Full Text] [Related]
29. Emicizumab: A Review in Haemophilia A. Blair HA Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880 [TBL] [Abstract][Full Text] [Related]
30. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415 [TBL] [Abstract][Full Text] [Related]
31. Utilization of emicizumab in acquired hemophilia A: A case report. Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753 [TBL] [Abstract][Full Text] [Related]
32. Early changes in bleeding perception and quality of life in children and adolescents receiving emicizumab prophylaxis for severe haemophilia A without inhibitor. Marro M; Petit AF; Falaise C; Roche M; Gensollen S; Hezard N; Boucekine M; Auquier P; Chambost H; Saultier P Haemophilia; 2023 Jan; 29(1):397-400. PubMed ID: 36524683 [No Abstract] [Full Text] [Related]
33. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A. Díaz-Ricart M; Isola IM; Escolar G Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480 [TBL] [Abstract][Full Text] [Related]
34. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Coppola A; Castaman G; Santoro RC; Mancuso ME; Franchini M; Marino R; Rivolta GF; Santoro C; Zanon E; Sciacovelli L; Manca S; Lubrano R; Golato M; Tripodi A; Rocino A; Haemophilia; 2020 Nov; 26(6):937-945. PubMed ID: 33094880 [TBL] [Abstract][Full Text] [Related]
35. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050 [No Abstract] [Full Text] [Related]
36. The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia. Brown LJ; La HA; Li J; Brunner M; Snoke M; Kerr AM Haemophilia; 2020 Aug; 26 Suppl 5():21-29. PubMed ID: 32935399 [TBL] [Abstract][Full Text] [Related]
37. Real-world data on the use of emicizumab in patients with haemophilia A with and without inhibitors in Singapore. Lee MW; Cheong MA; Ng HJ; Tien SL; Lam JCM Ann Acad Med Singap; 2023 Nov; 52(11):580-589. PubMed ID: 38920147 [TBL] [Abstract][Full Text] [Related]
38. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. Mahlangu JN BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367 [TBL] [Abstract][Full Text] [Related]
39. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X. Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217 [TBL] [Abstract][Full Text] [Related]
40. Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab. Garcia J; Zia A Pediatr Blood Cancer; 2021 May; 68(5):e28942. PubMed ID: 33559300 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]